<DOC>
	<DOCNO>NCT02499627</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , phase 2 clinical trial aim evaluate efficacy safety combination bendamustine brentuximab vedotin first salvage therapy patient relapse refractory Hodgkin 's lymphoma PTCL . A total 25 patient PTCL , 40 Hodgkin 's lymphoma expect treated accord treatment protocol . In study , intravenous bendamustine administer dose 90 mg/m2 day 1 2 brentuximab give intravenously total dose 1.8 mg/kg day 1 21 days-based cycle , 6 cycle . All patient achieve CR consider eligible peripheral blood stem cell mobilization ( perform granulocytecolony stimulate factor alone ) may proceed ASCT time cycle 4 .</brief_summary>
	<brief_title>A Phase II Study With Bendamustine Plus Brentuximab Vedotin Hodgkin 's Lymphoma CD30+ Peripheral T-cell Lymphoma First Salvage Setting : BBV Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lymphatic Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Inclusion criterion patient classical Hodgkin 's lymphoma : 1 . Patients first relapse primary refractory disease ( i.e . patient previously receive 1 line treatment ) . Patients must complete prior treatment radiation , chemotherapy , biologics , immunotherapy and/or investigational agent within least 5 halflives last dose treatment 2 . Histologicallyconfirmed CD30+ disease ( IHC BerH2 antibody ) 3 . Age 18 60 year . 4 . Fluorodeoxyglucose ( FDG ) avid measurable disease ( lymph node must long axis 1.5 cm regardless short axis long axis 1.1 1.5 short axis &gt; 1.0 cm ) document PET CT. 5 . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . The following required baseline laboratory data : absolute neutrophil count ( ANC ) ≥ 1500/μL , unless know marrow involvement due disease , platelets ≥ 75,000/μL , unless know marrow involvement due disease , bilirubin ≤ 1.5 x upper limit normal ( ULN ) ≤ 3 x ULN patient Gilbert 's disease , serum creatinine ≤ 1.5 X ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 X ULN . 7 . Serum Albumin ≥ 3 g/dL . 8 . Females childbearing potential must negative serum urine βhCG pregnancy test result within 7 day prior first dose therapy . Females nonchildbearing potential postmenopausal 1 year bilateral tubal ligation hysterectomy . 9 . Both female childbearing potential male partner childbearing potential must agree use effective contraceptive method study least 6 month follow last dose study drug . 10 . Male patient , even surgically sterilize ( i.e. , post vasectomy ) , : 1 . Agree practice effective barrier contraception entire study treatment period 6 month last dose study drug , 2 . Agree completely abstain heterosexual intercourse . 11 . Patients must provide write informed consent Exclusion criterion patient classical Hodgkin 's lymphoma : 1 . Previous treatment bendamustine brentuximab vedotin . 2 . Patients older 60 year treat adcetris bendamustine 3 . Prior autologous stem cell transplant . 4 . Known history follow cardiovascular condition : myocardial infarction within 2 year study entry ; NYHA class III IV heart failure ; cardiac arrhythmia ; angina ; electrocardiographic evidence acute ischemia conduction system abnormality ; recent evidence ( within 6 month first dose study drug ) leftventricular ejection fraction &lt; 50 % . 5 . History another primary malignancy within 3 year study entry ( follow exempt 3year limit : nonmelanoma skin cancer , curatively treat localized prostate cancer cervical carcinoma situ biopsy squamous intraepithelial lesion PAP smear ) . 6 . Known cerebral/meningeal disease ( HL etiology ) testicular involvement . 7 . Signs symptom progressive multifocal leukoencephalopathy ( PML ) . 8 . Preexisting Peripheral Neuropathy ≥ 2 . 9 . Any active systemic viral , bacterial , fungal infection require treatment antimicrobial therapy within 2 week prior first dose therapy . 10 . Current therapy systemic antineoplastic investigational agent . 11 . Therapy corticosteroid great equal 20 mg/day prednisone equivalent within 1 week prior first dose therapy . 12 . Women pregnant breastfeeding . 13 . Patients know hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin bendamustine . 14 . Known human immunodeficiency virus ( HIV ) positivity . 15 . Known hepatitis B surface antigen ( HBsAg ) positivity know suspect active hepatitis C infection . 16 . Patients dementia alter mental state would preclude understand render informed consent . Inclusion criteria patient peripheral Tcell lymphoma : 1 . Patients first relapse primary refractory PTCL ( i.e . patient previously receive one line treatment ) . Patients must complete prior treatment radiation , chemotherapy , biologics , immunotherapy and/or investigational agent least 4 week prior first dose therapy . 2 . Signed write informed consent . 3 . Age 18 60 year . 4 . Histologically confirm diagnosis PTCL , i.e . PTCLnot otherwise specify ( PTCLNOS ) , angioimmunoblastic T cell lymphoma ( AITL ) transform mycosis fungoides accord World Health Organization ( WHO ) 2008 classification . 5 . Histologically confirm CD30+ PTCL ( IHC BerH2 antibody ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 1 study entry . 7 . At least one site measurable disease two dimension compute tomography . Both nodal extranodal sit take consideration ( lymph node must long axis 1.5 cm regardless short axis long axis 1.1 1.5 cm short axis &gt; 1.0 cm ) . 8 . Hematology value within follow limit : 1. absolute neutrophil count ( ANC ) ≥ 1500/mm3 independent growth factor support ; 2. platelet ≥ 75,000/mm3 ≥ 50,000/mm3 bone marrow involvement independent transfusion support ; 3. hemoglobin level ≥ 8 g/dL . 9 . Biochemical value within follow limit : 1. alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 x upper limit normal ( ULN ) ; 2. total bilirubin &lt; 1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin ) ; 3. serum creatinine ≤ 2 x ULN ; 4. serum albumin ≥ 3 g/dL . 10 . Women childbearing potential must negative pregnancy test within 7 day receive study medication must agree use effective contraception , define : oral contraceptive , double barrier method practice true abstinence sexual intercourse study least 6 month last dose study drug . 11 . Male subject female partner childbearing potential must willing use appropriate method contraception practice true abstinence sexual intercourse study least 6 month last dose study drug . Exclusion criteria patient peripheral Tcell lymphoma : 1 . Diagnosis cutaneous Tcell lymphoma , anaplastic largecell lymphoma ( ALCL ) , mycosis fungoides Sézary Syndrome . 2 . Patients complete prior treatment chemotherapy and/or investigational agent within least 5 halflives last dose prior treatment . 3 . Previous treatment bendamustine brentuximab vedotin . 4 . Patients older 60 year treat adcetris bendamustine 5 . Prior autologous stem cell transplant . 6 . Known hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin bendamustine . 7 . Any serious active disease comorbid medical condition ( accord investigator 's decision ) . 8 . Prior history malignancy lymphoma ( except history complete resection basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year . 9 . Preexisting peripheral neuropathy grade ≥ 2 . 10 . Signs symptom progressive multifocal leukoencephalopathy ( PML ) . 11 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 12 . Pregnant lactate female men woman childbearing potential willing use adequate method birth control duration study positive pregnancy test day 1 first dose study drug . 13 . Central nervous system disease ( meningeal and/or brain involvement lymphoma ) testicular involvement . 14 . History clinically relevant liver renal insufficiency ; significant pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance . 15 . Known history follow cardiovascular condition : myocardial infarction within 2 year study entry ; NYHA class III IV heart failure ; cardiac arrhythmia ; angina ; electrocardiographic evidence acute ischemia conduction system abnormality ; recent evidence ( within 6 month first dose study drug ) leftventricular ejection fraction &lt; 50 % . 16 . Active systemic , viral , bacterial , fungal infection require systemic antibiotic within 2 week prior first dose study drug . 17 . Known human immunodeficiency virus ( HIV ) positivity . 18 . Known hepatitis B surface antigen ( HBsAg ) positivity know suspect active hepatitis C infection . 19 . Prior allogeneic stem cell transplant 20 . Patients dementia alter mental state would preclude understand render informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin</keyword>
	<keyword>PTCL</keyword>
	<keyword>CD30+</keyword>
</DOC>